550 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B Sell
Article Searches
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo http://www.zacks.com/stock/news/355437/bayer-obtains-full-rights-to-vitrakvi-from-lillys-loxo?cid=CS-ZC-FT-355437 Feb 19, 2019 - Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice http://www.zacks.com/stock/news/355011/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-ZC-FT-355011 Feb 15, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853 Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings http://www.zacks.com/stock/news/354851/5-drug-biotech-stocks-set-to-beat-estimates-in-q4-earnings?cid=CS-ZC-FT-354851 Feb 14, 2019 - Let us take a look at five favorable stocks, poised to beat estimates this earnings season.
Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down http://www.zacks.com/stock/news/354559/teva-teva-q4-earnings-miss19-view-weak-shares-down?cid=CS-ZC-FT-354559 Feb 14, 2019 - Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report http://www.zacks.com/stock/news/354373/key-takeaways-from-eli-lillys-lly-q4-earnings-report?cid=CS-ZC-FT-354373 Feb 13, 2019 - Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp http://www.zacks.com/research-daily/212965/top-stock-reports-for-disney-eli-lilly-us-bancorp?cid=CS-ZC-FT-212965 Feb 12, 2019 - Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp
Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake http://www.zacks.com/stock/news/353577/lilly-to-begin-exchange-offer-for-sale-of-balance-elanco-stake?cid=CS-ZC-FT-353577 Feb 11, 2019 - Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco
Teva (TEVA) to Report Q4 Earnings: What's in the Cards? http://www.zacks.com/stock/news/353410/teva-teva-to-report-q4-earnings-whats-in-the-cards?cid=CS-ZC-FT-353410 Feb 08, 2019 - While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-ZC-FT-353405 Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.

Pages: 123456789...55

<<<Page 4>